You’re using a public version of DrugPatentWatch with 5 free searches available | Register to unlock more free searches. CREATE FREE ACCOUNT

Last Updated: April 26, 2024

Claims for Patent: 9,638,697

✉ Email this page to a colleague

« Back to Dashboard

Summary for Patent: 9,638,697

Title:	Monoclonal antibody specifically recognizing asparagine synthetase
Abstract:	It is an object of the present invention to provide a monoclonal antibody, which is suitable for the quantitative analysis of asparagine synthetase in a cell. The present invention provides a monoclonal antibody which specifically recognizes asparagine synthetase that is present in a cell.
Inventor(s):	Hamakubo; Takao (Tokyo, JP), Mochizuki; Yasuhiro (Tokyo, JP), Iwanari; Hiroko (Tokyo, JP), Arai; Osamu (Tokyo, JP), Kitoh; Toshiyuki (Aichi, JP), Tsurusawa; Masahito (Aichi, JP)
Assignee:	THE UNIVERSITY OF TOKYO (Tokyo, JP) INSTITUTE OF IMMUNOLOGY CO., LTD. (Tokyo, JP) AICHI MEDICAL UNIVERSITY (Aichi, JP)
Application Number:	14/348,803
Patent Claims:	1. A monoclonal antibody which is produced by a hybridoma having Accession No. NITE BP-1141 or Accession No. NITE BP-1142. 2. A hybridoma having Accession No. NITE BP-1141 or Accession No. NITE BP-1142. 3. A reagent for measuring asparagine synthetase present in a cell, which comprises the monoclonal antibody according to claim 1. 4. A method for measuring asparagine synthetase present in a cell, which comprises allowing the monoclonal antibody according to claim 1 to come into contact with a cell containing asparagine synthetase. 5. The method according to claim 4, which measures asparagine synthetase present in a leukemia cell or an ovarian cancer cell. 6. A method for evaluating the sensitivity of leukemia or ovarian cancer to L-asparaginase, which comprises measuring asparagine synthetase by the method according to claim 4 and then evaluating the sensitivity of leukemia or ovarian cancer to L-asparaginase based on the measurement results. 7. A method for evaluating the sensitivity of leukemia or ovarian cancer to L-asparaginase, which comprises measuring asparagine synthetase by the method according to claim 5 and then evaluating the sensitivity of leukemia or ovarian cancer to L-asparaginase based on the measurement results.

Details for Patent 9,638,697

Glossary

Subscribe to access the full database, or Try a Trial
Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Recordati Rare Diseases, Inc.	ELSPAR	asparaginase	For Injection	101063	01/10/1978	⤷ Try a Trial	2031-10-03
>Applicant	>Tradename	>Biologic Ingredient	>Dosage Form	>BLA	>Approval Date	>Patent No.	>Expiredate

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.